Rhythm Pharma rallies on Q1 IMCIVREE sales beat and fast HO launch uptake
Rhythm Pharmaceuticals shares jumped after reporting Q1 2026 results showing IMCIVREE net product revenue of $60.1 million and accelerating demand following its acquired hypothalamic obesity launch. The company said it received more than 150 U.S. patient start forms in the first six weeks after the March 19, 2026 FDA approval.
1) What’s moving the stock
Rhythm Pharmaceuticals is surging after releasing first-quarter 2026 financial results and a business update that highlighted stronger IMCIVREE commercialization momentum and rapid early demand in acquired hypothalamic obesity (HO). The update emphasized both revenue growth and concrete early-launch metrics, including more than 150 patient start forms in the first six weeks following the U.S. approval.
2) The key numbers investors are reacting to
For Q1 2026, Rhythm reported $60.1 million in global IMCIVREE net product revenue, with $36.9 million in the U.S. and $23.2 million internationally. The company reported a Q1 net loss of $56.7 million (loss of $0.83 per share) and ended March 31, 2026 with $340.6 million in cash, cash equivalents, and short-term investments, alongside 2026 non-GAAP operating expense guidance of $385 million to $415 million.
3) Why the HO launch matters now
The HO indication is a meaningful expansion because it opens IMCIVREE to a new patient population beyond the company’s earlier genetic obesity indications. Rhythm is pointing investors to tangible evidence of launch traction—patient start forms and multi-region regulatory progress—while it scales commercialization and works through additional geographies, including an ongoing Japanese review for acquired HO.